Roche Confident Spark Therapeutics Acquisition Will Complete In First Half

 
• By John Davis

US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.  

Basel
Basle, the headquarters of Swiss big pharma, Roche. • Source: Shutterstock

More from Deals

More from Business